Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K RayR Scott WrightDavid KallendWolfgang KoenigLawrence A LeiterFrederick J RaalJenna A BischTara RichardsonMark JarosPeter L J WijngaardJohn J P Kasteleinnull nullPublished in: The New England journal of medicine (2020)
Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.).